Help us create better MS treatments.

Participate in an important breakthrough that could potentially reduce relapses and improve the quality of life for thousands of relapsing multiple sclerosis patients like you.


We need your help to advance research in multiple sclerosis.

Relapsing multiple sclerosis (RMS) affects approximately 85% of people with MS. While many treatments have been approved for the condition, there is an unmet need for a treatment that can reduce disability progression and disease activity.

This is why our team at SC3 Research is dedicated to testing and finding better treatments for this disease. In order to do this, we need your help! 

Why you should join:

Help shape the future of MS treatment

Learn more about disease-modifying therapies for multiple sclerosis while participating in the development of better treatments.

Participate in an important breakthrough

Your time can make an invaluable contribution to complete recent breakthroughs. Without your participation in these clinical trials, there may never be better treatment options for MS.

Become a leading voice in MS research

People with MS are the key to finding treatments for the disease. You have a unique opportunity to contribute to our scientific understanding of a condition

Get access to study treatments and care at zero cost

As a participant, you'll receive study-related medical care and treatment. You'll be provided with free regular health monitoring throughout the study.

What are the risks of taking part in a clinical study?

There are no guarantees that a participant’s health will improve

The investigational drug may cause side effects

Some of the procedures may carry their own risks or may be uncomfortable

Participant safety is the top priority of every clinical study. Governments have strict rules to protect the safety and privacy of study participants.

What happens if I decide to take part in a clinical study?

  • First, you will be asked to read and sign an informed consent form (ICF) to show that you understand the study and that you agree to be involved. The ICF describes what will happen and when.
  • Once this is signed, the study team will carry out some assessments to see if you are eligible.
  • If you are eligible, you will be asked to come to the clinic  for some health checks. The number of clinic visits and time between them will differ.

The FENhance 1 Study

We’re conducting the FENhance 1 (GN41851) study. The FENhance 1 study is assessing how safe and effective an investigational study drug is in treating Relapsing Multiple Sclerosis (RMS) and Secondary Progressive Multiple Sclerosis, compared to an approved comparator drug (a drug that is already being used to treat patients with RMS). We are also looking at worsening of disability and lesions visible on MRI scans.

We have already seen results in previous clinical trials. With your participation, we can complete the breakthrough!

About the Investigational Drug

What is Fenebrutinib?

Fenebrutinib is a new drug being investigated for the treatment of relapsing and primary progressive MS. Phase 2 and 3 trials are currently recruiting people with relapsing and progressive MS.

The immune system is a complete network of cells that work together to protect the body from harmful substances.

B cells are one component of this network. They produce antibodies to help the body fight harmful substances, but in some autoimmune conditions, such as multiple sclerosis, B cells can overreact and cause harm.

The investigational drug, fenebrutinib, is designed to work by suppressing B cells.

Fenebrutinib has been studied in more than 1,200 people to date across several inflammatory diseases

How does fenebrutinib work?

Fenebrutinib is part of a new class of drugs called Bruton’s tyrosine kinase (BTK) inhibitors. BTK is a molecule that affects the activity of some immune cells. Stopping BTK working properly reduces the activity of these immune cells.

These cells have been linked to MS relapses and progression. Researchers believe reducing their activity could reduce the damage caused to nerves.

Unlike the other BTK inhibitors, fenebrutinib has a unique, reversible mechanism. Roche, the company behind fenebrutinib, argue that this reversible mechanism will create a better, safer treatment against MS compared to its competitors.

How is fenebrutinib taken?

As a tablet, once daily.

How long is the study?

The total length of the trial is at least 96 weeks/4.5 years (including screening and follow-up),.The study staff will work with you to find convenient times for these visits.


Eligibility Criteria

Eligibility criteria help researchers achieve accurate and meaningful results. You may be able to participate in the study if you are: 





≥18 Years & ≤ 55 Years




Healthy Volunteers

To be able to take part in this clinical trial, participants must be between the ages of 18 and 55 and have been diagnosed with RMS or SPMS. Participants must also have scored no more than 5.5 on the Extended Disability Status Scale (EDSS), and must be able to complete the 9-hole peg test and timed 25-foot walk test.

Find out if you qualify for this clinical study.

Please answer the questions below to see if you may be eligible for the FENhance Study.

Completing this questionnaire does not obligate you to participate in the study. Your answers will help determine if you may be eligible. If your answers indicate you may be eligible, you will have the opportunity to contact a clinic site near you to learn more about the study.


If you have problems accessing the website or have questions regarding the study please contact the research team via email ( or phone (16262502070 ext 799)